Profil
Patrick Loustau is President, Chief Executive Officer & Director at Granite Bio AG since 2025.
Formerly, Mr. Loustau was Senior Vice President-Global Commercialization at Bristol Myers Squibb Co. in 2014, President at Zafgen, Inc. from 2014 to 2016, and Senior VP-Global Marketing & Medical Affairs at Novo Nordisk A until 2010.
Education includes graduate studies at Université de Paris XI Paris Sud.
Aktive Positionen von Patrick Loustau
| Unternehmen | Position | Beginn |
|---|---|---|
Granite Bio AG
Granite Bio AG BiotechnologyHealth Technology Operates as a biotechnology company which develops therapeutic antibodies | Vorstandsvorsitzender | 01.02.2025 |
Ehemalige bekannte Positionen von Patrick Loustau
| Unternehmen | Position | Ende |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Präsident | 19.07.2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.04.2014 |
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.07.2010 |
Ausbildung von Patrick Loustau
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Université de Paris XI Paris Sud
Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Granite Bio AG
Granite Bio AG BiotechnologyHealth Technology Operates as a biotechnology company which develops therapeutic antibodies | Health Technology |
















